

ABSTRACT

A cancer gene therapeutic drug of the present invention includes a carrier cell to be infected with an oncolytic virus, so as to make the oncolytic virus act on a tumor cell within a living body, wherein the carrier cell is selected from A549 cell, 293 cell, SW626 cell and HT-3 cell, showing a potent antitumor effect. Because of use of such cell line having high antitumor effect both *in vitro* and *in vivo* as the carrier cell, the cancer gene therapeutic drug provides more potent antitumor effect in comparison to those of conventional carrier cells.